Home › Companies › Royalty Pharma plc › 2025-2026

Royalty Pharma plc 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Royalty Pharma plc’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

18Reported items
562Asset managers
9,528Fund votes
June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 18 items on Royalty Pharma plc’s Form 8-K, filed June 4, 2026: 18 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Royalty Pharma plc in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Royalty Pharma plc

These tallies are Royalty Pharma plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Royalty Pharma plc — official shareholder meeting results, meeting held June 4, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Pablo Legorreta	458,242,360	29,448,236	168,578	--	20,320,929	94%	Not verified	—
Elect Director: Ted Love, M.D.	464,556,053	23,135,217	167,904	--	20,320,929	95%	Not verified	—
Elect Director: Bonnie Bassler, Ph.D.	486,078,663	1,615,471	165,040	--	20,320,929	99.6%	Not verified	—
Elect Director: Vlad Coric, M.D.	433,218,530	54,472,087	168,557	--	20,320,929	89%	Not verified	—
Elect Director: Catherine Engelbert	485,200,369	2,492,809	165,996	--	20,320,929	99.4%	Not verified	—
Elect Director: Carole Ho, M.D.	487,136,029	557,922	165,223	--	20,320,929	99.8%	Not verified	—
Elect Director: David Hodgson	479,933,527	7,733,381	192,266	--	20,320,929	98%	Not verified	—
Elect Director: Gregory Norden	481,576,664	6,090,949	191,561	--	20,320,929	99%	Not verified	—
Elect Director: Elizabeth Weatherman	487,564,658	128,998	165,518	--	20,320,929	99.9%	Not verified	—
2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers	476,044,602	11,067,486	747,086	--	20,320,929	98%	Not verified	—
3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm	506,307,829	832,217	1,040,057	--	--	99.8%	Not verified	—
4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditors' report for the fiscal year ended Dece	487,151,335	98,040	609,799	--	20,320,929	99.9%	Not verified	—
5. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts	478,165,378	8,935,552	758,244	--	20,320,929	98%	Not verified	—
6. To re-appoint Ernst & Young as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders	506,752,136	384,952	1,043,015	--	--	99.9%	Not verified	—
7. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor	487,092,662	575,800	190,712	--	20,320,929	99.8%	Not verified	—
8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares	474,475,427	12,499,628	884,119	--	20,320,929	97%	Not verified	—
9. To authorize the Board of Directors to allot shares	469,111,384	18,568,396	179,394	--	20,320,929	96%	Not verified	—
10. To authorize the Board of Directors to allot shares without rights of pre-emption	445,653,078	42,016,406	189,690	--	20,320,929	91%	Not verified	—

Source: Royalty Pharma plc, Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Royalty Pharma plc 2025-2026 meeting

Each item below shows how the 562 asset managers that disclosed a Royalty Pharma plc vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Royalty Pharma plc’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Pablo Legorreta

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 458,242,360AGAINST: 29,448,236

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Pablo Legorreta

Royalty Pharma plc’s own tally for this item (“Elect Director: Pablo Legorreta”): 458,242,360 for, 29,448,236 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,207,914 for, 451,760 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,207,914AGAINST: 451,760ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Pablo Legorreta” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,904	75	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

2. Elect Director: Ted Love, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 464,556,053AGAINST: 23,135,217

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Ted Love, M.D.

Royalty Pharma plc’s own tally for this item (“Elect Director: Ted Love, M.D.”): 464,556,053 for, 23,135,217 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 123,287,020 for, 1,372,654 against, 139,847 abstained, 373 not voted.

FOR

FOR: 123,287,020AGAINST: 1,372,654ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Ted Love, M.D.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,923,905	9,032	0	For
Vanguard	8,258,234	22,745	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	0	596,935	0	Against
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. Elect Director: Bonnie Bassler, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 486,078,663AGAINST: 1,615,471

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Bonnie Bassler, Ph.D.

Royalty Pharma plc’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 486,078,663 for, 1,615,471 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,639,672 for, 2 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,639,672AGAINST: 2ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Bonnie Bassler, Ph.D.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,977	2	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

4. Elect Director: Vlad Coric, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 433,218,530AGAINST: 54,472,087

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Vlad Coric, M.D.

Royalty Pharma plc’s own tally for this item (“Elect Director: Vlad Coric, M.D.”): 433,218,530 for, 54,472,087 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 116,134,376 for, 8,505,297 against, 139,847 abstained, 373 not voted.

FOR

FOR: 116,134,376AGAINST: 8,505,297ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Vlad Coric, M.D.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	6,027,226	2,253,752	0	Mixed
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,740	2,937,710	0	Against
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	0	528,307	0	Against
Equitable	360,849	138,721	0	Mixed
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

5. Elect Director: Catherine Engelbert

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 485,200,369AGAINST: 2,492,809

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Catherine Engelbert

Royalty Pharma plc’s own tally for this item (“Elect Director: Catherine Engelbert”): 485,200,369 for, 2,492,809 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,648,668 for, 6 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,648,668AGAINST: 6ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Catherine Engelbert” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,973	6	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

6. Elect Director: Carole Ho, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 487,136,029AGAINST: 557,922

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Carole Ho, M.D.

Royalty Pharma plc’s own tally for this item (“Elect Director: Carole Ho, M.D.”): 487,136,029 for, 557,922 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,648,672 for, 2 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,648,672AGAINST: 2ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Carole Ho, M.D.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,977	2	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

7. Elect Director: David Hodgson

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 479,933,527AGAINST: 7,733,381

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: David Hodgson

Royalty Pharma plc’s own tally for this item (“Elect Director: David Hodgson”): 479,933,527 for, 7,733,381 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,408,287 for, 240,385 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,408,287AGAINST: 240,385ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: David Hodgson” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,961	16	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

8. Elect Director: Gregory Norden

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 481,576,664AGAINST: 6,090,949

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Gregory Norden

Royalty Pharma plc’s own tally for this item (“Elect Director: Gregory Norden”): 481,576,664 for, 6,090,949 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,625,561 for, 23,113 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,625,561AGAINST: 23,113ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Gregory Norden” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,963	16	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

9. Elect Director: Elizabeth Weatherman

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 487,564,658AGAINST: 128,998

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Elizabeth Weatherman

Royalty Pharma plc’s own tally for this item (“Elect Director: Elizabeth Weatherman”): 487,564,658 for, 128,998 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 124,625,577 for, 23,097 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,625,577AGAINST: 23,097ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Election of Directors: Elizabeth Weatherman” at Royalty Pharma plc, 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	8,280,979	0	For
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

10. 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A…

Outcome not verifiedEXTRAORDINARY TRANSACTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 474,475,427AGAINST: 12,499,628

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares.

Royalty Pharma plc’s own tally for this item (“8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares”): 474,475,427 for, 12,499,628 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 124,743,850 for, 35 against, 20,002 abstained, 373 not voted.

FOR

FOR: 124,743,850AGAINST: 35ABSTAIN: 20,002NOT VOTED: 373

Largest asset managers voting on “Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary ” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,941	35	2	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,149,197	0	0	For
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

11. 10. To authorize the Board of Directors to allot shares without rights of pre-emption

Outcome not verifiedSHAREHOLDER RIGHTS AND DEFENSESReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 445,653,078AGAINST: 42,016,406

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Authorize the Board to allot shares without rights of pre-emption (special resolution).

Royalty Pharma plc’s own tally for this item (“10. To authorize the Board of Directors to allot shares without rights of pre-emption”): 445,653,078 for, 42,016,406 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 122,896,845 for, 1,867,042 against, 373 not voted.

FOR

FOR: 122,896,845AGAINST: 1,867,042NOT VOTED: 373

Largest asset managers voting on “Authorize the Board to allot shares without rights of pre-emption (special resolution).” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	6,810,309	1,470,669	Mixed
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

12. Authorize the Board to allot shares.

No official matchCAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

99.8% of fund votes cast · no official result

FOR

Details: votes by 106 asset managers

The 106 asset managers below reported 124,582,564 for, 181,323 against, 373 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 124,582,564AGAINST: 181,323NOT VOTED: 373

Largest asset managers voting on “Authorize the Board to allot shares.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	8,280,930	48	For
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

13. 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 476,044,602AGAINST: 11,067,486

Details: description as filed, official tally, votes by 562 asset managers

Description as filed by funds: A non-binding advisory vote to approve executive compensation.

Royalty Pharma plc’s own tally for this item (“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 476,044,602 for, 11,067,486 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 105 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,952	25	2	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	524,331	3,976	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Fund voting reports, all 105 managers: 124,302,283 for, 370,466 against, 139,849 abstained, 373 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 486 asset managers voting on “A non-binding advisory vote to approve executive compensation.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Vote
Capital Group	44,668,043	0	For
Morgan Stanley	35,316,977	0	For
Fidelity	18,924,572	0	For
BlackRock	18,369,446	0	For
Swedbank Robur Fonder AB	11,586,693	0	For
State Street	8,342,985	10,152	For
GEODE CAPITAL MANAGEMENT, LLC	7,872,174	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	6,580,633	0	For
Caledonia (Private) Investments Pty Ltd	5,051,550	0	For
BAILLIE GIFFORD OVERSEAS LTD	4,663,534	0	For
Victory Capital	3,867,577	0	For
Invesco	3,607,096	0	For
BAILLIE GIFFORD & CO	3,585,063	0	For
BAILLIE GIFFORD & CO LTD	3,315,813	0	For
Vanguard	3,292,401	0	For
Charles Schwab	3,032,105	0	For
Amundi	566,094	2,108,226	Mixed
Northern Trust	2,527,141	0	For
T. Rowe Price	2,384,371	0	For
NEW SOUTH CAPITAL MANAGEMENT INC	2,376,063	0	For
Regal Partners Ltd	2,307,376	0	For
Dorsey Asset Management, LLC	2,276,570	0	For
London LGPS CIV Ltd	2,204,941	0	For
Legal & General Investment Management Ltd	2,109,289	12,160	For
AQR	1,925,686	0	For

Institutional-manager reports, all 486 managers: 253,223,858 for, 7,856,569 against, 1,536,477 abstained, 22,438 not voted. Showing the 25 largest; see all in the interactive database.

14. 5. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 478,165,378AGAINST: 8,935,552

Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: Approve on a non-binding advisory basis our U.K. directors' remuneration report for the fiscal year ended December 31, 2025.

Royalty Pharma plc’s own tally for this item (“5. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts”): 478,165,378 for, 8,935,552 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Fund voting reports: 103 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report for the fiscal year ended Dece” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,958	18	2	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Fund voting reports, all 103 managers: 124,236,183 for, 366,483 against, 140,349 abstained, 373 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 16 asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report for the fiscal year ended Dece” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	18,369,446	0	0	For
Caledonia (Private) Investments Pty Ltd	5,051,550	0	0	For
Vident Advisory, LLC	14,802	0	0	For
Ethic Inc.	0	4,232	100	Against
Argent Trust Co	2,842	0	0	For
R. W. Roge & Company, Inc.	1,000	0	0	For
Formidable Asset Management, LLC	721	0	0	For
Keel Point, LLC	648	0	0	For
Beacon Bank & Trust	641	0	0	For
Smithfield Trust Co	603	0	0	For
Midwest Trust Co	500	0	0	For
Haverford Trust Co	144	0	0	For
Glenview Trust Co	122	0	0	For
Pinnacle Financial Partners, Inc.	121	0	0	For
Roberts Wealth Advisors, LLC	3	0	0	For
Ariadne Wealth Management, LP	1	0	0	For

Institutional-manager reports, all 16 managers: 23,443,144 for, 4,232 against, 100 abstained.

15. 3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 506,307,829AGAINST: 832,217

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.

Royalty Pharma plc’s own tally for this item (“3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm”): 506,307,829 for, 832,217 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 107 asset managers below reported 124,639,172 for, 139,847 abstained, 373 not voted.

FOR

FOR: 124,639,172ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.” at Royalty Pharma plc, 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	8,280,977	0	For
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

16. 6. To re-appoint Ernst & Young as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 506,752,136AGAINST: 384,952

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.

Royalty Pharma plc’s own tally for this item (“6. To re-appoint Ernst & Young as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report an”): 506,752,136 for, 384,952 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 107 asset managers below reported 124,639,172 for, 2 against, 139,847 abstained, 373 not voted.

FOR

FOR: 124,639,172AGAINST: 2ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next genera” at Royalty Pharma plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Capital Group	37,466,076	0	0	For
Fidelity	23,338,697	0	0	For
Morgan Stanley	9,932,937	0	0	For
Vanguard	8,280,977	2	0	For
BlackRock	7,765,898	0	0	For
Victory Capital	6,902,683	0	0	For
Invesco	3,090,537	0	0	For
Charles Schwab	2,940,450	0	0	For
Transamerica	2,667,195	0	0	For
Advisor Managed Portfolios	2,500,000	0	0	For
Brighthouse	2,009,350	0	139,847	Mixed
T. Rowe Price	1,410,745	0	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	0	For
Goldman Sachs	922,117	0	0	For
First Trust	757,711	0	0	For
Pacific Life	738,489	0	0	For
TIAA	727,951	0	0	For
Pacer Funds Trust	681,715	0	0	For
State Street	596,935	0	0	For
JPMorgan	593,735	0	0	For
AQR	559,517	0	0	For
SEI	528,307	0	0	For
Equitable	499,570	0	0	For
ALPS ETF Trust	493,508	0	0	For
Thrivent	490,731	0	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

17. 7. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 487,092,662AGAINST: 575,800

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.

Royalty Pharma plc’s own tally for this item (“7. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor”): 487,092,662 for, 575,800 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 107 asset managers below reported 124,658,674 for, 139,847 abstained, 373 not voted.

FOR

FOR: 124,658,674ABSTAIN: 139,847NOT VOTED: 373

Largest asset managers voting on “Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory audit” at Royalty Pharma plc, 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	8,280,979	0	For
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

18. 4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 487,151,335AGAINST: 98,040

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2025.

Royalty Pharma plc’s own tally for this item (“4. To approve receipt of the Company's U.K. statutory accounts together with the Company's U.K. statutory reports, including the directors' report, the strategic report, the directors' remuneration report and the auditor”): 487,151,335 for, 98,040 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 106 asset managers below reported 124,604,539 for, 139,849 abstained, 373 not voted.

FOR

FOR: 124,604,539ABSTAIN: 139,849NOT VOTED: 373

Largest asset managers voting on “Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports fo” at Royalty Pharma plc, 2025-2026
Asset manager	For	Abstain	Vote
Capital Group	37,466,076	0	For
Fidelity	23,338,697	0	For
Morgan Stanley	9,932,937	0	For
Vanguard	8,280,977	2	For
BlackRock	7,765,898	0	For
Victory Capital	6,902,683	0	For
Invesco	3,090,537	0	For
Charles Schwab	2,940,450	0	For
Transamerica	2,667,195	0	For
Advisor Managed Portfolios	2,500,000	0	For
Brighthouse	2,009,350	139,847	Mixed
T. Rowe Price	1,410,745	0	For
MUTUAL FUND SERIES TRUST	1,073,575	0	For
Goldman Sachs	922,117	0	For
First Trust	757,711	0	For
Pacific Life	738,489	0	For
TIAA	727,951	0	For
Pacer Funds Trust	681,715	0	For
State Street	596,935	0	For
JPMorgan	593,735	0	For
AQR	559,517	0	For
SEI	528,307	0	For
Equitable	499,570	0	For
ALPS ETF Trust	493,508	0	For
Thrivent	490,731	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

Not shown here: this season’s fund filings also report 2 items from the meeting of May 12, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Royalty Pharma plc shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 436,790,000 shares outstanding at the time of that meeting.

Fund voting reports: top Royalty Pharma plc shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Capital Group	8.58%
2	Fidelity	5.34%
3	Morgan Stanley	2.27%
4	Vanguard	1.90%
5	BlackRock	1.78%
6	Victory Capital	1.58%
7	Invesco	0.71%
8	Charles Schwab	0.67%
9	Transamerica	0.61%
10	Advisor Managed Portfolios	0.57%

Institutional-manager reports: top Royalty Pharma plc shareholders by shares voted on “A non-binding advisory vote to approve executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Capital Group	10.23%
2	Morgan Stanley	8.09%
3	Fidelity	4.33%
4	BlackRock	4.21%
5	Swedbank Robur Fonder AB	2.65%
6	State Street	1.91%
7	GEODE CAPITAL MANAGEMENT, LLC	1.80%
8	ADAGE CAPITAL PARTNERS GP, L.L.C.	1.51%
9	Caledonia (Private) Investments Pty Ltd	1.16%
10	BAILLIE GIFFORD OVERSEAS LTD	1.07%

Reported Royalty Pharma plc holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Royalty Pharma plc holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Legorreta G. Pablo	23.30%	13D
RPI US Partners 2019, LP	22.50%	DEF14A
Morgan Stanley	8.91%	DEF14A
Capital International Investors	7.50%	DEF14A
FMR LLC	6.39%	DEF14A
BlackRock	5.93%	13F
FMR (Fidelity)	5.76%	13F
R & H Trust Co. (Guernsey) Limited	5.55%	13D
PL RPH Holdings, LLC	3.06%	DEF14A
State Street	2.52%	13F

Percentages above are of 436,790,000 shares outstanding, as reported by Royalty Pharma plc on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Royalty Pharma plc’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Royalty Pharma plc's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 562 asset managers reported how they voted in their SEC Form N-PX filings, covering 9,528 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Royalty Pharma plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Royalty Pharma plc proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.